# Study of YK012 in B-cell Acute Lymphoblastic Leukemia

> **NCT06580301** · PHASE1,PHASE2 · RECRUITING · sponsor: **Excyte Biopharma Ltd** · enrollment: 46 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** YK012

## Key facts

- **NCT ID:** NCT06580301
- **Lead sponsor:** Excyte Biopharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06580301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06580301, "Study of YK012 in B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT06580301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*